Study Evaluating Vabicaserin in Subjects With Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.

Key facts

Study ID

NCT00563706

Run by

Pfizer

People needed

199

Starts

2007-12-01

Expected to finish

2008-06-01

Last updated by the study team

2014-03-20

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Generally healthy, men and women, aged 18 to 65.
• Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year.
• Ability to remain hospitalized for the duration of the screening period and for 4 weeks of double-blind treatment.

You may not qualify if…

• Current Axis I primary psychiatric diagnosis other than schizophrenia (DSM-IV-TR criteria).
• Current diagnosis or history of substance abuse or dependence (DSM-IV-TR criteria), including alcohol (except for nicotine), within 3 months before baseline (day -1).
• Subjects taking high or chronic doses of benzodiazepine at the screening evaluation who, in the investigator's judgment, would be likely to have severe withdrawal symptoms upon discontinuation.

Where it is running

• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Cerritos, California, United States
• Pfizer Investigational Site — Escondido, California, United States
• Pfizer Investigational Site — Garden Grove, California, United States
• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Aventura, Florida, United States
• Pfizer Investigational Site — Hollywood, Florida, United States
• Pfizer Investigational Site — Kissimmee, Florida, United States
• Pfizer Investigational Site — Hoffman Estates, Illinois, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Lake Charles, Louisiana, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Rockville, Maryland, United States
• Pfizer Investigational Site — Hamilton, New Jersey, United States
• Pfizer Investigational Site — Willingboro, New Jersey, United States
• Pfizer Investigational Site — Cedarhurst, New York, United States
• Pfizer Investigational Site — Holliswood, New York, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Butner, North Carolina, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.